Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.49 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.46 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17948970 | 1.00 | KDM4E (0.50) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL1475228 | 0.85 | KDM4E (0.53) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL17942409 | 0.81 | GPR119 (0.50) | KDM4EPKMGPR119STS | |
| SCHEMBL29529671 | 0.81 | GPR119 (0.50) | KDM4EPKMGPR119STS | |
| SCHEMBL30833401 | 0.80 | KDM1A (0.44) | — | |
| SCHEMBL15103494 | 0.78 | GPR119 (0.56) | KDM4EPKMGPR119STS | |
| SCHEMBL17942351 | 0.78 | KDM4E (0.50) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL29529976 | 0.78 | KDM4E (0.50) | KDM4EPKMGPR119STSTGFBR1 | |
| SCHEMBL28385137 | 0.78 | GPR119 (0.37) | GPR119STS | |
| SCHEMBL19617395 | 0.78 | GPR119 (0.49) | KDM4EPKMGPR119STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | KDM4E 45/4885PKM 821/4885GPR119 3908/4885 |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | KDM4E 45/4885PKM 821/4885GPR119 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.